Quintiles has been named a preferred provider to a consortium of 14 global health product development partnerships (PDPs), leveraging the combined size of their pipelines to ensure the most cost-effective use of their research and development dollars.
PDPs are not-for-profit entities that advance global health by the discovery, development and delivery of effective and affordable medicines for global neglected diseases. The PDPs anticipate funding 128 clinical trials over the next two years.
The members are funded, in part, by the Bill and Melinda Gates Foundation, which has committed $10 billion over the next 10 years for the poorest countries, with a portion of that funding going to the PDPs. Funding also comes from government agencies and private entities.
Quintiles will partner with the consortium by providing one-step access to Quintiles’ global clinical development infrastructure and standards, particularly for infectious diseases such as HIV, malaria and tuberculosis.